Chas is the architect behind the Symbiotix (SBX) platform, drawing on his extensive experience in global health data innovation. His journey in health technology began in 2016, where he contributed to platforms like Hexcel, focusing on health records in Africa, and co-founded a blockchain-based Electronic Health Record (EHR) platform. His insight into global health was further shaped by his work as a consultant for The Global Fund (TGF) in Geneva, where he served on their private sector engagement team.

With over 25 years of professional experience, Chas has built expertise across marketing, business development in Technology, Asset Management, and Corporate Finance. He also co-founded Obsidian Sports, a Sports Advisory business, demonstrating his entrepreneurial versatility.

Chas holds a BA in Economics from Nottingham Business School.

Sam is an accomplished senior executive with two decades of experience in Health Care IT, delivering impactful results across the public and private sectors in the MEA, UK, and Asia regions. As the General Manager of Dedalus AMEA, he drives innovation and growth in the healthcare technology space. Previously, he spearheaded key initiatives at Orion Health and played a pivotal role in the launch of GE’s Caradigm, a groundbreaking joint venture between Microsoft and GE.

Sam’s expertise extends to his tenure as Business Development Director and MEA Strategy Lead for Microsoft Health Solutions Group, where he led transformative projects. At Cerner, he was instrumental in securing the landmark $400M BT London project. Beyond his professional achievements, Sam is also the author of NFT In Me, a thought-provoking exploration of data monetisation using NFTs.

Anil is an entrepreneur and technology leader with over 20 years of experience driving innovation in banking, insurance, and financial services. He has led the creation of platforms such as blockchain-based token distribution, small business banking solutions, and AI-powered wealth advisory tools, with his AI wealth adviser recognised by Innovate UK in 2014. After Barclays, Anil co-founded Symbiotix, where he leads platform design, and 3003BC, which creates bespoke fragrances using AI. He holds an MSc in Computing Science from Newcastle University, a Certificate in Machine Learning from Stanford, and is pursuing a Cybersecurity certification from MIT.

Brendon’s career includes over 25 years of experience in Investment Banking in Finance and COO roles. These Banks include Credit Suisse, HSBC and Goldman Sachs. Alongside these full-time banking roles, he has also been the COO for Kinect Hub a global healthcare records and crypto company, and the COO for a large Hong Kong family office specialising in Technology Investments and Startups.

Additionally, he has consulted to Corporate Finance Houses on M&A deals including renewable energy transactions, large commercial and residential property transactions, and luxury brand disposals.

With a career that began in the commercial teams of big pharma, Robbie has spent the last four years in the biotech sector, specialising in scientific operations to prepare novel drugs for market authorisation.

Drawing on his experience in life sciences, Robbie co-founded Symbiotix, where he plays a central role in driving the company’s success by leading business development and overseeing internal operations.

In addition to his work at Symbiotix, Robbie has a proven track record as a business development consultant, helping companies at all stages of growth refine their narratives, develop robust growth strategies, and achieve investment readiness, with a strong focus on healthcare, beauty, and business services sectors.

Bryn was previously at Benevolent AI for 7 years latterly as SVP Drug Discovery, applying new AI approaches to early drug Target ID and validation. He spent around 20 years in various parts of Pfizer mostly in applied computational biology and drug project ideation. Bryn has spent a long time working in pharma data pre-competitive data innovation and was the initiator and leader of the IMI Open PHACTS project.

Avery has significant experience as both a computational and wet lab biology researcher, where he has worked on genome engineering and machine learning projects. He has performed doctoral research in computational biomedicine at New York University Medical School and has worked on the Cell and Molecular Biology team at the Boston-based gene therapy start-up SalioGen Therapeutics. Avery additionally holds a degree in economics and has work experience in various sectors, including technology, sports management, and insurance.

Lara supports business development at Symbiotix, driving strategic growth through in-depth market analysis and client engagements. With experience across various healthcare providers in emerging markets, she brings a nuanced understanding of global health systems to align solutions with client needs. She holds an MSc in Global Healthcare Management and a BSc in Applied Medical Sciences from University College London, blending scientific knowledge with business acumen to support Symbiotix’s growth in the healthcare sector.

Mark Timney has deep experience in the biopharmaceutical industry. Mark currently serves as Chief Executive Officer at Attralus and is also a strategic advisor to health care companies and investment groups.

Throughout a career defined by deep operational and commercial experience, Mark has held senior roles in companies that include The Medicines Company, Merck & Co., Purdue Pharmaceuticals, Zeneca Group, ICI Pharmaceuticals and Roussel Labs, and has led markets that include the United States, Japan, South Korea, Australia and New Zealand.

Mark’s most recent executive role was CEO and Board member of The Medicines Company which was subsequently sold to Novartis for $9.7B.

Lord Patel brings decades of expertise in health and social care, working at the highest levels of national and international policy development. He is a Senior Board Director at Cygnet Health and has served as the UK Government’s National Strategic Director for the National Institute for Mental Health England. He chaired the Mental Health Act Commission and led the Delivering Race Equality Board, one of the largest mental health race equality programs in the UK. Awarded an OBE for Services to Ethnic Minority Health Issues, he also holds prestigious academic honors, including an honorary Doctorate of Health.

John Markels, Ph.D., has worked for over 35 years in pharmaceuticals, mostly at Merck & Co, where he retired as President of Global Vaccines in 2022. He led vaccine discovery, supply, global marketing, and strategy teams. He’s been a Sangamo Board member since 2020, Dr. Markels has global experience, having lived in the US, Latin America, and Europe. He holds a Ph.D. in chemical engineering from UC Berkeley and a B.S. from the University of Delaware.

Nick King is the founder and CEO of Data Kinetic, a groundbreaking firm that translates experimental AI advancements into practical business solutions. With a career rooted in the early days of cloud computing and artificial intelligence, Nick has influenced key technologies at several major tech companies. Prior to launching Data Kinetic in 2023, he played a vital role in developing Google Cloud, led the enterprise evolution of Android, and contributed to Microsoft’s initial Azure data and AI team. His leadership extended to VMware, Cisco, Snowplow, and DataRobot, creating solutions for diverse sectors such as Formula 1, energy, public services, and finance. Currently, Nick focuses on applying AI innovations in healthcare, longevity science, and pharmaceuticals.

A global executive with 25 years of experience driving growth and innovation in life sciences, genomics and medtech. With a strong foundation in general management, strategy and IT, plus extensive leadership roles at organisations like G42 / M42, SAP, Smith & Nephew, and Johnson & Johnson, he has consistently delivered impactful results. Francesco has also served as an advisor to startups and established organisations, leveraging his expertise in consulting, in scaling businesses, in international expansion, and in strategic partnerships, achieving significant revenue growth, operational efficiencies, and market differentiation. A thought leader in health tech and precision medicine with a passion for transformative leadership.